$500M Cash Pool, $150M Buyback Authorized for Galapagos in Binding Gilead Collaboration
summarizeSummary
Galapagos and Gilead have entered into a binding agreement to collaborate on advancing Ouro Medicines' clinical-stage T cell engager program (gamgertamig) for autoimmune diseases. This definitive agreement follows Gilead's acquisition of Ouro Medicines for $1.675 billion upfront and up to $500 million in contingent milestones. Crucially for Galapagos, the framework agreement provides significantly improved financial terms, including a $500 million cash pool for independent deployment and authorization for up to $150 million in share buybacks. This development solidifies the strategic collaboration that was previously reported as "advanced discussions" on March 23rd. The deal provides Galapagos with substantial financial flexibility and a high-potential, first-in-class asset, significantly advancing its pipeline and capital allocation strategy. For Gilead, the collaboration leverages its commercial capabilities to accelerate the development of a promising asset acquired through Ouro. Traders will be watching for further updates on the gamgertamig program's clinical progress and how Galapagos utilizes its newly secured capital.
At the time of this announcement, GLPG was trading at $28.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $22.59 to $37.78. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.